warrenhochfeld

Aclaris Therapeutics Inc ACRS buy opportunity

Long
NASDAQ:ACRS   Aclaris Therapeutics, Inc.
Buy at a discount ahead of the 24/12/17 PDUFA decision on A-101 in seborrheic keratosis
Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.